Overview

The Effect of Liraglutide on Left Ventricular Function in Chronic Heart Failure Patients With and Without Type 2 Diabetes Mellitus

Status:
Completed

Trial end date:
2015-10-01

Target enrollment:

Participant gender:

Summary

Type 2 diabetes (T2D) is a major risk factor of chronic heart failure (CHF). Glycemic control in patients with the combination of T2D and CHF is complicated and the currently available treatments have proven to be inadequate in clinical trials. Objectives To investigate the effect of Liraglutide compared to placebo on left ventricular ejection fraction (LVEF) in CHF patients with and without T2D. Multicenter, randomized, double blind study of 240 patients with documented systolic CHF (50% with T2DM) will be randomised. The effect of Liraglutide on left ventricular systolic and diastolic function will be evaluated by advanced echocardiography Primary outcome parameter is change in LVEF from visit 1 to week 24.

Phase:

N/A

Details

Lead Sponsor:

Flyvbjerg, Allan, DMSc

Collaborator:

Novo Nordisk A/S

Treatments:

Liraglutide